RECRUITING

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Description

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

Conditions

CancerChildhood CancerChemotherapy-induced Peripheral Neuropathy
Talk to us

Related Conditions:

CancerChildhood CancerChemotherapy-induced Peripheral Neuropathy

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale New Haven Health Smilow York Street Hospital, New Haven, Connecticut, United States, 06520

Trumbull

Yale New Haven Health Park Avenue Medical Center, Trumbull, Connecticut, United States, 06611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * History of childhood cancer (\<21 years of age at diagnosis)
  • * Current age five years or older (due to availability of validated measures for CIPN in this age group)
  • * History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
  • * CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \<18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)
  • * Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
  • * Inability to sit still for at least 15 minutes
  • * Diagnosis of neuropathy prior to cancer treatment
  • * Active cancer diagnosis or cancerous skin lesion
  • * Central nervous system tumor (due to lack of validated measures for CIPN in this population)
  • * Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.

Ages Eligible for Study

5 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Rozalyn Rodwin, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2026-09